GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pharmicell Co 005690.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

8,030

+0.88%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩114.06bn

FY2016FY2025

Net income

₩40.29bn

FY2016FY2025

Free cash flow

₩33.56bn

FY2016FY2025

Shareholders' equity

₩123.88bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩114.06bn₩64.85bn₩56.23bn₩60.18bn₩51.81bn₩37.75bn₩32.48bn₩28.35bn₩25.20bn₩27.84bn
Gross profit₩50.68bn₩21.33bn₩15.49bn₩23.82bn₩23.71bn₩17.78bn₩13.03bn₩11.80bn₩8.07bn₩10.22bn
Research and development₩6.71bn₩7.89bn₩6.54bn₩6.88bn₩6.99bn₩4.31bn₩4.87bn₩4.51bn₩3.60bn₩2.73bn
Operating income₩34.30bn₩4.66bn₩1.30bn₩8.87bn₩10.94bn₩7.23bn₩1.96bn₩260.2m−₩4.46bn−₩1.87bn
Net income₩40.29bn₩6.33bn₩3.58bn₩8.26bn₩9.45bn₩5.24bn₩4.35bn−₩12.68bn−₩39.20bn−₩676.7m
Diluted earnings per share672.09105.6259.69137.82157.6687.4472.52-211.54-653.87-11.29

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩157.17bn₩99.26bn₩92.52bn₩109.65bn₩94.33bn₩69.74bn₩63.27bn₩59.12bn₩63.75bn₩101.95bn
Total liabilities₩33.30bn₩12.83bn₩12.12bn₩32.98bn₩30.46bn₩12.64bn₩11.75bn₩11.63bn₩7.76bn₩7.36bn
Debt₩8.00bn—————₩3.00bn₩3.00bn₩396.0m—
Shareholders' equity₩123.88bn₩86.44bn₩80.40bn₩76.66bn₩63.87bn₩57.11bn₩51.52bn₩47.49bn₩55.99bn₩94.60bn
Shares outstanding60m60m60m60m60m60m60m60m60m60m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩41.05bn₩3.50bn₩11.81bn₩7.91bn−₩5.22bn₩8.98bn−₩75.5m₩3.40bn−₩2.01bn₩989.0m
Capital spending−₩7.49bn−₩4.34bn−₩6.02bn−₩18.96bn−₩4.32bn−₩742.7m−₩1.66bn−₩4.68bn−₩4.27bn−₩3.85bn
Free cash flow₩33.56bn−₩840.0m₩5.79bn−₩11.04bn−₩9.54bn₩8.24bn−₩1.74bn−₩1.27bn−₩6.28bn−₩2.86bn
Dividends paid−₩1.20bn—————————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩38.98bn₩36.69bn₩34.62bn₩25.65bn₩26.76bn₩27.03bn₩21.47bn₩14.59bn
Gross profit₩17.07bn₩17.39bn₩14.38bn₩11.57bn₩12.14bn₩12.60bn₩8.14bn₩5.11bn
Operating income₩13.23bn₩13.08bn₩9.62bn₩8.14bn₩8.16bn₩8.38bn₩3.14bn₩1.28bn
Net income₩10.38bn₩11.71bn₩15.67bn₩8.78bn₩7.38bn₩8.46bn₩4.15bn₩714.0m
Diluted earnings per share173.13195.29261.44146.40123.19141.0669.3011.91
Cash from operations₩16.43bn−₩1.46bn₩17.27bn₩8.78bn₩16.04bn−₩1.03bn₩95.0m₩5.89bn
Capital spending−₩6.53bn−₩1.28bn−₩6.49bn−₩622.0m−₩283.0m−₩91.0m−₩194.0m−₩467.0m
Free cash flow₩9.89bn−₩2.74bn₩10.78bn₩8.16bn₩15.75bn−₩1.13bn−₩99.0m₩5.42bn
Total assets₩184.15bn₩168.10bn₩157.17bn₩130.02bn₩120.94bn₩106.03bn₩99.26bn₩91.72bn
Debt₩19.02bn₩13.94bn₩8.00bn₩8.00bn₩8.00bn———
Shareholders' equity₩143.37bn₩132.78bn₩123.88bn₩110.43bn₩101.36bn₩93.71bn₩86.44bn₩82.57bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue23.8%24.7%16.3%
Operating income56.9%36.5%—
Net income69.6%50.4%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin40.2%37.7%39.7%38.5%
Operating margin21.8%16.6%17.5%11.0%
Net margin26.1%19.8%19.0%3.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings21.678.4101.782.082.8197.8117.1-57.7-8.7-459.8
Price to sales7.67.76.511.315.127.515.725.813.611.2

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2024.

FY2025
Paid in the year20.00
  • 10-for-1 split · 19 Dec 2011
  • 1-to-0.4235 reverse split · 27 Oct 2008
  • 11-for-10 split · 23 Dec 1997

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.